Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy-Reference-Cited by-同舟云学术

Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy

Published:2021-08-02 Issue:4 Volume:4 Page:1306-1321
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Moehle Mark S.¹²^ORCID,Bender Aaron M.¹,Dickerson Jonathan W.¹,Foster Daniel J.¹³^ORCID,Qi Aidong¹,Cho Hyekyung P.¹,Donsante Yuping⁴,Peng Weimin¹,Bryant Zoey¹,Stillwell Kaylee J.¹,Bridges Thomas M.¹,Chang Sichen¹,Watson Katherine J.¹,O’Neill Jordan C.¹,Engers Julie L.¹,Peng Li¹,Rodriguez Alice L.¹,Niswender Colleen M.¹³,Lindsley Craig W.¹^ORCID,Hess Ellen J.⁴,Conn P. Jeffrey¹³,Rook Jerri M.¹

Affiliation:

1. Department of Pharmacology, Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States

2. Department of Pharmacology & Therapeutics, Center for Translational Research in Neurodegeneration, University of Florida, Gainesville, Florida 32610, United States

3. Vanderbilt Kennedy Center, Vanderbilt University, Nashville, Tennessee 37232, United States

4. Department of Pharmacology & Chemical Biology, Emory University, Atlanta, Georgia 30322, United States

Funder

National Institute of Neurological Disorders and Stroke

Congressionally Directed Medical Research Programs

Michael J. Fox Foundation for Parkinson's Research

National Institute of Mental Health

Ancora Innovation

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology